# Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults

> **NCT02951052** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **ViiV Healthcare** · enrollment: 618 (actual)

## Conditions studied

- Infection, Human Immunodeficiency Virus
- HIV Infections

## Interventions

- **DRUG:** Cabotegravir (CAB) tablet
- **DRUG:** Rilpivirine (RPV) tablet
- **DRUG:** Cabotegravir - Injectable Suspension (CAB LA)
- **DRUG:** Rilpivirine - Injectable Suspension (RPV LA)
- **DRUG:** 2 NRTIs plus an INI, NNRTI, or PI

## Key facts

- **NCT ID:** NCT02951052
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-10-28
- **Primary completion:** 2018-05-29
- **Final completion:** 2029-12-31
- **Target enrollment:** 618 (ACTUAL)
- **Last updated:** 2025-12-31

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02951052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02951052, "Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02951052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*